ARK Investment Management LLC lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 23.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 160,625 shares of the company's stock after selling 47,898 shares during the period. ARK Investment Management LLC owned approximately 0.08% of Cellebrite DI worth $2,705,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. purchased a new stake in shares of Cellebrite DI during the third quarter worth approximately $23,402,000. Pembroke Management LTD increased its position in shares of Cellebrite DI by 104.9% in the 2nd quarter. Pembroke Management LTD now owns 1,535,726 shares of the company's stock valued at $18,352,000 after purchasing an additional 786,310 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Cellebrite DI by 26.8% in the 1st quarter. Acadian Asset Management LLC now owns 2,896,497 shares of the company's stock valued at $32,062,000 after purchasing an additional 612,787 shares in the last quarter. Meitav Investment House Ltd. lifted its position in shares of Cellebrite DI by 29.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock worth $34,797,000 after purchasing an additional 473,293 shares during the last quarter. Finally, Ashford Capital Management Inc. grew its stake in shares of Cellebrite DI by 23.5% during the first quarter. Ashford Capital Management Inc. now owns 1,841,240 shares of the company's stock worth $20,401,000 after purchasing an additional 350,140 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.
Cellebrite DI Stock Down 1.0 %
NASDAQ:CLBT traded down $0.18 during trading hours on Friday, reaching $18.61. 1,434,023 shares of the company's stock were exchanged, compared to its average volume of 1,148,436. Cellebrite DI Ltd. has a 1-year low of $7.22 and a 1-year high of $21.00. The firm has a market capitalization of $3.83 billion, a price-to-earnings ratio of -12.01, a P/E/G ratio of 2.63 and a beta of 1.50. The company has a 50-day moving average of $17.62 and a 200 day moving average of $14.31.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. The firm had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a negative return on equity of 748.06% and a negative net margin of 82.28%. The business's revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company posted $0.09 earnings per share. Research analysts forecast that Cellebrite DI Ltd. will post 0.31 EPS for the current fiscal year.
Analyst Ratings Changes
CLBT has been the topic of a number of analyst reports. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft boosted their target price on Cellebrite DI from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. Needham & Company LLC increased their price target on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Thursday. Craig Hallum boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Bank of America increased their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI currently has a consensus rating of "Buy" and an average price target of $20.29.
Read Our Latest Analysis on Cellebrite DI
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
